{
    "Trade/Device Name(s)": [
        "CardioPhase\u00ae hsCRP",
        "N Rheumatology Standard SL"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Products GmbH",
    "510(k) Number": "K212559",
    "Predicate Device Reference 510(k) Number(s)": [
        "K964527",
        "K991385",
        "K033908",
        "K943997",
        "K001647"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NQD"
    ],
    "Summary Letter Date": "June 22, 2022",
    "Summary Letter Received Date": "June 23, 2022",
    "Submission Date": "June 23, 2022",
    "Regulation Number(s)": [
        "21CFR866.5270"
    ],
    "Regulation Name(s)": [
        "C-reactive protein immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "chemistry"
    ],
    "Analyte(s)": [
        "C-reactive protein (CRP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Heparin plasma",
        "EDTA plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "BN II System",
        "BN ProSpec System",
        "BN Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Particle-enhanced immunoassay",
        "Nephelometry"
    ],
    "Methodologies": [
        "Immunonephelometry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for CardioPhase hsCRP immunoassay and N Rheumatology Standard SL calibrator for quantitative measurement of C-reactive protein in serum and plasma using nephelometry",
    "Indications for Use Summary": "Quantitative determination of C-reactive protein (CRP) in human serum, heparin plasma, and EDTA plasma for detection and evaluation of infection, tissue injury, inflammatory disorders, associated diseases, and as an independent risk marker for future cardiovascular disease",
    "fda_folder": "Immunology"
}